A. Alexopoulos

1.2k total citations
40 papers, 993 citations indexed

About

A. Alexopoulos is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. Alexopoulos has authored 40 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in A. Alexopoulos's work include Cancer Treatment and Pharmacology (20 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (7 papers). A. Alexopoulos is often cited by papers focused on Cancer Treatment and Pharmacology (20 papers), HER2/EGFR in Cancer Research (8 papers) and Advanced Breast Cancer Therapies (7 papers). A. Alexopoulos collaborates with scholars based in Greece, France and India. A. Alexopoulos's co-authors include Michalis Leotsinidis, Vassilis Georgoulias, M. Veslemes, Ph. Palamidas, A. Rapti, E. Papadakis, Ioannis G. Vlachonikolis, Xanthi Tsiafaki, G. Rigatos and Alexandros Ardavanis and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Chemosphere.

In The Last Decade

A. Alexopoulos

39 papers receiving 950 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Alexopoulos Greece	13	550	314	183	127	116	40	993
Kafil Akhtar India	19	120 0.2×	169 0.5×	60 0.3×	190 1.5×	53 0.5×	129	1.0k
Guoqing Qian United States	24	372 0.7×	399 1.3×	210 1.1×	573 4.5×	44 0.4×	52	1.3k
Aldo Cavallini Italy	26	357 0.6×	271 0.9×	358 2.0×	664 5.2×	119 1.0×	69	1.8k
L.J. Hahn Taiwan	20	189 0.3×	159 0.5×	250 1.4×	458 3.6×	52 0.4×	24	1.8k
Hitoshi Iwata Japan	15	183 0.3×	144 0.5×	163 0.9×	202 1.6×	25 0.2×	73	786
J Dich Sweden	11	120 0.2×	140 0.4×	369 2.0×	112 0.9×	68 0.6×	16	1.1k
Yuji Togashi Japan	20	524 1.0×	82 0.3×	55 0.3×	328 2.6×	37 0.3×	35	1.3k
Wen Zhuang China	21	328 0.6×	186 0.6×	137 0.7×	353 2.8×	80 0.7×	45	1.3k
Kuo-Hsuan Hsu Taiwan	20	535 1.0×	678 2.2×	192 1.0×	223 1.8×	73 0.6×	62	1.2k
Vijayvel Jayaprakash United States	22	445 0.8×	225 0.7×	82 0.4×	191 1.5×	12 0.1×	37	1.1k

Countries citing papers authored by A. Alexopoulos

Since Specialization

Citations

This map shows the geographic impact of A. Alexopoulos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Alexopoulos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Alexopoulos more than expected).

Fields of papers citing papers by A. Alexopoulos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Alexopoulos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Alexopoulos. The network helps show where A. Alexopoulos may publish in the future.

Co-authorship network of co-authors of A. Alexopoulos

This figure shows the co-authorship network connecting the top 25 collaborators of A. Alexopoulos. A scholar is included among the top collaborators of A. Alexopoulos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Alexopoulos. A. Alexopoulos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alexopoulos, A., Charisios Karanikiotis, Alexandros Ardavanis, et al.. (2022). Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study). Anticancer Research. 42(2). 1031–1041. 4 indexed citations

Mantzourani, Ioanna, Anastasios Nikolaou, Yiannis Kourkoutas, et al.. (2022). Microbiological stability and sensorial valorization of thyme and oregano essential oils alone or combined with ethanolic pomegranate extracts in wine marinated pork meat. International Journal of Food Microbiology. 386. 110022–110022. 9 indexed citations

Koumarianou, Anna, Flora Zagouri, Christos Papadimitriou, et al.. (2020). ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer. Breast Cancer Research and Treatment. 182(1). 85–96. 3 indexed citations

Papadopoulos, Savvas, et al.. (2018). Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer– A Single Centre Prospective Observational Study. In Vivo. 32(2). 303–311. 24 indexed citations

Alexopoulos, A., et al.. (2016). Hypermetabolic Calcified Lymph Nodes on 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomography in a Case of Treated Ovarian Cancer Recurrence: Residual Disease or Benign Formation?. Molecular Imaging and Radionuclide Therapy. 25(2). 91–96. 1 indexed citations

Kourlaba, Georgia, Vasiliki Rapti, A. Alexopoulos, et al.. (2015). Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study. BMC Health Services Research. 15(1). 307–307. 10 indexed citations

Kimbaris, Athanasios, Ioanna Mantzourani, Stavros Plessas, et al.. (2015). Antimicrobial activity of essential oils of cultivated oregano (Origanum vulgare), sage (Salvia officinalis), and thyme (Thymus vulgaris) against clinical isolates ofEscherichia coli,Klebsiella oxytoca, andKlebsiella pneumoniae. Microbial Ecology in Health and Disease. 26(0). 23289–23289. 114 indexed citations

Ardavanis, Alexandros, et al.. (2005). Safety and Efficacy of Trastuzumab Every 3 Weeks Combined with Cytotoxic Chemotherapy in Patients with HER2-Positive Recurrent Breast Cancer: Findings from a Case Series. Oncology Research and Treatment. 28(11). 558–564. 5 indexed citations

Alexopoulos, A., et al.. (2005). Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?. European Journal of Cancer Care. 14(3). 267–271. 6 indexed citations

10.

Ardavanis, Alexandros, et al.. (2005). Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. British Journal of Cancer. 92(4). 645–650. 50 indexed citations

11.

Leotsinidis, Michalis, et al.. (2005). Toxic and essential trace elements in human milk from Greek lactating women: Association with dietary habits and other factors. Chemosphere. 61(2). 238–247. 132 indexed citations

12.

Alexopoulos, A., et al.. (2004). Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer. Annals of Oncology. 15(6). 891–895. 41 indexed citations

13.

Alexopoulos, A., et al.. (2004). In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: General concepts and future perspectives. Seminars in Oncology. 31(2 Suppl 5). 25–30. 5 indexed citations

14.

Mavroudis, D., A. Alexopoulos, Nikolaos Malamos, et al.. (2003). Salvage Treatment of Metastatic Breast Cancer with Docetaxel and Carboplatin. Oncology. 64(3). 207–212. 17 indexed citations

15.

Georgoulias, Vassilis, E. Papadakis, A. Alexopoulos, et al.. (2001). Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. The Lancet. 357(9267). 1478–1484. 276 indexed citations

16.

Alexopoulos, A., Ch. Kouroussis, Nikolaos Malamos, et al.. (2001). Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: A multicenter phase II study. Annals of Oncology. 12(6). 793–798. 4 indexed citations

17.

Agelaki, Sofia, A. Alexopoulos, Charalambos Kouroussis, et al.. (2001). Salvage treatment with irinotecan and gemcitabine in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. European Journal of Cancer. 37. S197–S198. 1 indexed citations

18.

Mavroudis, Dimitriοs, A. Alexopoulos, Nikolaos Ziras, et al.. (2000). Front-line treatment of advanced breast cancer with docetaxel and epirubicin: A multicenter phase II study. Annals of Oncology. 11(10). 1249–1254. 27 indexed citations

19.

Kouroussis, Ch., Anna Potamianou, T. Giannakakis, et al.. (1999). Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: A multicenter dose-escalation study. Annals of Oncology. 10(5). 547–552. 33 indexed citations

20.

Alexopoulos, C.G., et al.. (1999). A phase II study of the effectiveness of docetaxel (Taxotere) in women with advanced breast cancer previously treated with polychemotherapy. Cancer Chemotherapy and Pharmacology. 44(3). 253–258. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact